(UBI) Ubisoft Entertainment - Ratings and Ratios
Action-Adventure, Open-World, Shooter, RPG, Strategy
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 53.9% |
| Value at Risk 5%th | 71.4% |
| Relative Tail Risk | -19.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.20 |
| Alpha | -59.85 |
| CAGR/Max DD | -0.46 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.647 |
| Beta | 0.479 |
| Beta Downside | 0.856 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.33% |
| Mean DD | 39.40% |
| Median DD | 36.51% |
Description: UBI Ubisoft Entertainment November 15, 2025
Ubisoft Entertainment SA (ticker UBI) is a French-based developer, publisher and distributor of interactive entertainment across consoles, PC, mobile and tablet platforms, operating globally with a mix of physical and digital sales. The firm creates full-cycle game content-including narrative design, animation, gameplay mechanics and proprietary engines-while also licensing its technology to third-party studios.
Key metrics from the most recent fiscal year (FY 2023) show revenue of €2.2 billion, a 7 % YoY increase driven primarily by strong performance of live-service titles (e.g., “Assassin’s Creed Valhalla” extensions) and a 12 % rise in digital-only sales. Free cash flow stood at €300 million, reflecting a 15 % operating margin after a modest increase in R&D spend to 14 % of revenue, a common industry benchmark for studios investing in next-gen engines. The sector’s growth is underpinned by the ongoing console cycle (PlayStation 5/Xbox Series X) and expanding mobile gaming spend, which together account for roughly 30 % of Ubisoft’s total addressable market.
Given the company’s pipeline of high-visibility IP releases in 2024 (e.g., “Avatar: Frontiers of Pandora”) and its strategic push into subscription-based game services, analysts should monitor the conversion rate of active monthly users to recurring revenue as a leading indicator of future cash generation. For a deeper dive into Ubisoft’s valuation dynamics and comparable peer analysis, a quick look at ValueRay’s data tools can help surface the most relevant forward-looking metrics.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (-128.3m TTM) > 0 and > 6% of Revenue (6% = 241.3m TTM) |
| FCFTA 0.32 (>2.0%) and ΔFCFTA 43.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.41% (prev 23.02%; Δ -18.61pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.34 (>3.0%) and CFO 1.45b > Net Income -128.3m (YES >=105%, WARN >=100%) |
| Net Debt (-668.2m) to EBITDA (563.9m) ratio: -1.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (131.2m) change vs 12m ago 6.49% (target <= -2.0% for YES) |
| Gross Margin 83.67% (prev 47.77%; Δ 35.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 88.73% (prev 60.35%; Δ 28.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.47 (EBITDA TTM 563.9m / Interest Expense TTM 108.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.69
| (A) 0.04 = (Total Current Assets 1.14b - Total Current Liabilities 959.2m) / Total Assets 4.31b |
| (B) -0.04 = Retained Earnings (Balance) -161.3m / Total Assets 4.31b |
| (C) 0.04 = EBIT TTM 158.7m / Avg Total Assets 4.53b |
| (D) 0.29 = Book Value of Equity 792.8m / Total Liabilities 2.75b |
| Total Rating: 0.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.97
| 1. Piotroski 6.0pt |
| 2. FCF Yield 60.87% |
| 3. FCF Margin 34.29% |
| 4. Debt/Equity 1.34 |
| 5. Debt/Ebitda -1.18 |
| 6. ROIC - WACC (= 1.85)% |
| 7. RoE -7.40% |
| 8. Rev. Trend -14.31% |
| 9. EPS Trend -13.89% |
What is the price of UBI shares?
Over the past week, the price has changed by +0.76%, over one month by -9.96%, over three months by -27.08% and over the past year by -51.19%.
Is UBI a buy, sell or hold?
What are the forecasts/targets for the UBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 60% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.8 | -37.7% |
UBI Fundamental Data Overview December 17, 2025
Market Cap EUR = 845.6m (845.6m EUR * 1.0 EUR.EUR)
P/E Forward = 12.6904
P/S = 0.4486
P/B = 0.5463
P/EG = 2.3907
Beta = -0.377
Revenue TTM = 4.02b EUR
EBIT TTM = 158.7m EUR
EBITDA TTM = 563.9m EUR
Long Term Debt = 1.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 359.6m EUR (from shortTermDebt, last quarter)
Debt = 2.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -668.2m EUR (from netDebt column, last quarter)
Enterprise Value = 2.27b EUR (845.6m + Debt 2.09b - CCE 668.4m)
Interest Coverage Ratio = 1.47 (Ebit TTM 158.7m / Interest Expense TTM 108.0m)
FCF Yield = 60.87% (FCF TTM 1.38b / Enterprise Value 2.27b)
FCF Margin = 34.29% (FCF TTM 1.38b / Revenue TTM 4.02b)
Net Margin = -3.19% (Net Income TTM -128.3m / Revenue TTM 4.02b)
Gross Margin = 83.67% ((Revenue TTM 4.02b - Cost of Revenue TTM 656.9m) / Revenue TTM)
Gross Margin QoQ = 48.57% (prev 90.84%)
Tobins Q-Ratio = 0.53 (Enterprise Value 2.27b / Total Assets 4.31b)
Interest Expense / Debt = 2.30% (Interest Expense 48.1m / Debt 2.09b)
Taxrate = 1.10% (-1.80m / -163.2m)
NOPAT = 156.9m (EBIT 158.7m * (1 - 1.10%))
Current Ratio = 1.18 (Total Current Assets 1.14b / Total Current Liabilities 959.2m)
Debt / Equity = 1.34 (Debt 2.09b / totalStockholderEquity, last quarter 1.56b)
Debt / EBITDA = -1.18 (Net Debt -668.2m / EBITDA 563.9m)
Debt / FCF = -0.48 (Net Debt -668.2m / FCF TTM 1.38b)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.98% (Net Income -128.3m / Total Assets 4.31b)
RoE = -7.40% (Net Income TTM -128.3m / Total Stockholder Equity 1.73b)
RoCE = 4.78% (EBIT 158.7m / Capital Employed (Equity 1.73b + L.T.Debt 1.59b))
RoIC = 5.71% (NOPAT 156.9m / Invested Capital 2.75b)
WACC = 3.86% (E(845.6m)/V(2.93b) * Re(7.78%) + D(2.09b)/V(2.93b) * Rd(2.30%) * (1-Tc(0.01)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 3.19%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.38b ; Y1≈905.6m ; Y5≈414.1m
Fair Price DCF = 60.43 (DCF Value 8.14b / Shares Outstanding 134.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -13.89 | EPS CAGR: -20.47% | SUE: -1.90 | # QB: 0
Revenue Correlation: -14.31 | Revenue CAGR: -23.46% | SUE: 0.60 | # QB: 0
EPS current Year (2026-03-31): EPS=-0.89 | Chg30d=-0.563 | Revisions Net=-4 | Growth EPS=-58.4% | Growth Revenue=-1.6%
EPS next Year (2027-03-31): EPS=0.76 | Chg30d=-0.265 | Revisions Net=+1 | Growth EPS=+185.8% | Growth Revenue=+10.1%